Previous 10 | Next 10 |
Voyager Therapeutics (NASDAQ:VYGR) +44% Pfizer in pact with Voyager Therapeutics to develop gene therapies Acer Therapeutics (NASDAQ:ACER) +14%. Kaixin Auto (NASDAQ:KXIN) +8% as POCCO EV orders surpassed 3000 units in September, +130% M/M Palantir Technologies (NYSE:PLTR)&...
HINGHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance covering the Company’s LIBERTY ® Robotic System. Globally, the Company now has 45 patents...
HINGHAM, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that China has become the latest global jurisdiction to issue a Notice of Allowance (NOA) for the Company’s innovative ‘One & Done’ guidewire technology, joining the Eur...
HINGHAM, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues its ongoing commitment to strengthen and broaden its capabilities as Giora Weisz, MD joined the Company’s Scientific Advisory Board (SAB). Dr. Weisz is a practicing interventional cardiol...
HINGHAM, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Global patent jurisdictions continue to recognize Microbot Medical Inc.’s (Nasdaq: MBOT) innovative ‘One & Done’ guidewire technology, as the Israel Intellectual Property Office has issued a Notice of Allowance (NOA)...
HINGHAM, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) has received official notification from the Japan Patent Office (JPO) that it intends to grant the Company a patent for its ‘One & Done’ guidewire technology for use with endoluminal int...
Microbot Medical ([[MBOT]] +2.3%) announces the completion of successful discussions with the U.S. FDA for its Self-Cleaning Shunt ((SCS)) allowing the company to apply for an Early Feasibility Study ((EFS)).The company reiterates its timeline for the First-in-Human clinical trial u...
HINGHAM, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced the completion of successful discussions with the U.S. Food and Drug Administration (FDA) for its Self-Cleaning Shunt (SCS). After review of the Company’s existing pre-clinical data,...
HINGHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to enhance its thought leadership capabilities with the addition of several new Scientific Advisory Board (SAB) members: Stephen B. Solomon, MD, a board-certified radiologist with clinical exper...
Microbot Medical (MBOT) announces the successful completion of an additional feasibility animal study using Liberty Robotic System, the fully disposable surgical robotic system.All the end points of navigating to a clot, crossing the clot, deploying a stent retriever, and manually r...
News, Short Squeeze, Breakout and More Instantly...
Microbot Medical Inc. Company Name:
MBOT Stock Symbol:
NASDAQ Market:
Microbot Medical Inc. Website:
BRAINTREE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announces it has received Institutional Review Board (IRB) approval and signed a clinical trial agreement with Memor...
Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company’s Pivotal Human Clinical Trial. The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY ® Endovascular R...
The first clinical case was performed at Brigham and Women’s Hospital The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY ® Endovascular Robotic Surgical System BRAINTREE, Mass., July 08, 2024 (G...